Skip to main content

Decoding Risk in Clinical & Public Health Practice: Absolute vs Relative Risk Reduction

What is the difference between Absolute Risk Reduction (ARR) and Relative Risk Reduction (RRR)? This is a common question from students and clinicians. Understanding these concepts is crucial for interpreting research findings, especially in clinical and public health settings.

Absolute Risk Reduction (ARR) refers to the difference in outcomes between a control group and a treated group in a clinical trial or an public health study.

Formula: ARR = CER - EER

Where: CER is the Control Event Rate (rate of event in the control group) and EER is the Experimental Event Rate (rate of event in the experimental group).

Example: Imagine a trial in which 10% of patients in the control group have an adverse event, and only 5% in the treatment group experience the same.

ARR = 10% - 5% = 5%

This means that the drug reduces the absolute risk of an adverse event by 5%. In total, 20 people need to be treated to prevent one event (the Number Needed to Treat, NNT).

Relative Risk Reduction (RRR) is the proportional reduction in outcomes between the treated and untreated groups. It's a way to contextualize the effectiveness of a treatment by considering the baseline risk.

Formula: RRR = (CER - EER)/{CER} times 100

Example: Continuing with the same drug trial, RRR = (10% - 5%) / (10%) times 100 = 50%

Interpretation: The drug reduces the relative risk of an adverse event by 50% compared to the control group.

Key Differences between ARR and RRR

1. Context: ARR gives you the actual change in risk, which is straightforward and easily interpretable. RRR puts this change in the context of the baseline risk, making the treatment appear seem more effective than it may actually be.

2. Impact: ARR is more useful for understanding the individual benefit of an intervention, while RRR is often more impressive for public health interventions where a small absolute change can have a large impact when scaled up.

3. Communication: RRR is often used in marketing or in media because it tends to produce a larger, more eye-catching number. However, this can be misleading if not used with the ARR, which provides a more direct measure of an intervention's effect.

4. Clinical Relevance: Knowing both ARR and RRR can aid in shared decision-making between clinicians and patients. While RRR can show the effectiveness of a treatment, ARR can guide on how much benefit an individual patient can expect.

By understanding both Absolute Risk Reduction and Relative Risk Reduction, clinicians and public health specialists can better interpret the data from clinical, public and epidemiological studies, and subsequently make more informed decisions about treatment options and public health interventions.

Comments

Popular posts from this blog

Protecting Against the "Quad-demic": Influenza, Covid-19, Norovirus and RSV

As the NHS braces for a challenging winter season, it is grappling with a "quad-demic" of health emergencies caused by influenza, Covid-19, norovirus, and respiratory syncytial virus (RSV). This confluence of viral threats poses a significant risk to public health in the UK as well as putting strain on healthcare resources, emphasising the importance of preventive measures to safeguard public health. Public health measures such a vaccination and good personal hygiene are pivotal in reducing the impact of these illnesses, particularly for vulnerable groups. The Four Viruses: What Are They? Influenza: A highly contagious respiratory infection that causes significant illness each winter. It can lead to severe complications, particularly in the elderly, young children, pregnant women, and those with chronic health conditions. Covid-19: Though its most acute phase has passed, Covid-19 remains a concern, especially as new variants of SA...

MPH Student Presentations on the NHS Care.Data Programme

As part of a session on primary care data in the Health Informatics module on the Imperial Master of Public Health Programme, I asked students to work in two groups to present arguments for and against the NHS Care.Data programme. Care.Data is an NHS programme that will extract data from the medical records held by general practitioners (GPs) in England. The Care.Data programme takes advantage of the very high level of use of electronic medical records by GPs in England. After extraction, data will be uploaded to the NHS Health and Social Care Information Centre (HSCIC). The data will then be used for functions such as health care planning, monitoring disease patterns and research. The programme has been controversial with proponents arguing that the programme will bring many benefits for the NHS and the population of England; and opponents arguing it is a major breach of privacy. You can view the two presentations to help inform you further about these arguments: Arguments fo...

How can we work successfully across the health and care system to make a success of Pharmacy First?

Pharmacies in England to begin treating patients for seven common conditions. How can we work successfully across the health and care system to make a success of Pharmacy First? 1. The Pharmacy First scheme aims to provide convenient access to healthcare through community pharmacies. Patients with minor ailments or common conditions can seek advice and treatment directly from their local pharmacy instead of visiting a general practice, urgent care centre or emergency department. The conditions covered by the scheme may vary depending on local funding arrangements and participation of pharmacies.  2, A potential problem with Pharmacy First is pharmacists misdiagnosing a patient's condition. It may also lead to delays in patients seeing doctors when medical assessment is needed. To mitigate these risks, appropriate safeguards and referral pathways should be established, ensuring timely medical assessment when necessary. The scheme will also increase the workload of pharmacies, thereb...